Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 419,400 shares, a drop of 25.6% from the February 28th total of 564,000 shares. Currently, 1.9% of the company’s stock are sold short. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Trading of Vigil Neuroscience

Several institutional investors and hedge funds have recently bought and sold shares of the company. Walleye Capital LLC boosted its position in shares of Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after acquiring an additional 92,217 shares during the last quarter. Verition Fund Management LLC purchased a new stake in Vigil Neuroscience in the third quarter valued at approximately $442,000. Point72 Asset Management L.P. lifted its position in Vigil Neuroscience by 7.7% during the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock valued at $5,440,000 after purchasing an additional 115,000 shares during the last quarter. Geode Capital Management LLC grew its stake in Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after buying an additional 66,712 shares in the last quarter. Finally, abrdn plc increased its holdings in shares of Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after buying an additional 293,461 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on VIGL shares. HC Wainwright decreased their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a report on Friday, March 14th. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Wedbush dropped their price objective on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, March 14th. Finally, William Blair began coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vigil Neuroscience presently has an average rating of “Buy” and an average target price of $16.25.

Vigil Neuroscience Stock Performance

Shares of VIGL opened at $1.91 on Monday. Vigil Neuroscience has a fifty-two week low of $1.49 and a fifty-two week high of $6.06. The business has a 50-day moving average of $2.35 and a 200 day moving average of $2.66. The firm has a market cap of $89.14 million, a P/E ratio of -0.93 and a beta of 1.82.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). As a group, research analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.